{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Esophagogastric+Junction&page=2", "query": { "condition": "Adenocarcinoma of Esophagogastric Junction", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Esophagogastric+Junction&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T10:21:43.901Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05159440", "title": "First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Gastric Cancer", "Pancreas Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "TORL-2-307-MAB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TORL Biotherapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2022-01-20", "completion_date": "2025-12-15", "has_results": false, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 5, "location_summary": "Fullerton, California • Los Angeles, California • Torrance, California + 2 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05159440" }, { "nct_id": "NCT06219941", "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "l-leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2023-12-13", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Santa Rosa, California + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06219941" }, { "nct_id": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pharmacokinetics of Zolbetuximab", "Gastric Cancer", "Gastro-esophageal Junction (GEJ) Cancer", "Pharmacokinetics of Oxaliplatin", "Pharmacokinetics of Fluorouracil Bolus (5-FU)" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-06-29", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 6, "location_summary": "Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03505320" }, { "nct_id": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Gastric Cancer", "Gastroesophageal Junction Carcinoma", "Esophageal Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "TJ033721 (givastomig)", "type": "DRUG" }, { "name": "TJ033721 (givastomig) , nivolumab, chemotherapy", "type": "DRUG" }, { "name": "TJ033721 (givastomig), chemotherapy", "type": "DRUG" }, { "name": "TJ033721 (givastomig), durvalumab, chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2021-06-29", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Layfayette", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900818" }, { "nct_id": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCAGN01876", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2017-04-25", "completion_date": "2021-11-09", "has_results": true, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 15, "location_summary": "Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126110" }, { "nct_id": "NCT03517488", "title": "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Carcinoma", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Non-small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Endometrial Carcinoma", "Mesothelioma", "Neuroendocrine Carcinoma", "Cervical Cancer", "Small Cell Lung Carcinoma", "Squamous Cell Carcinoma of the Anus", "Castration-Resistant Prostate Carcinoma", "Nasopharyngeal Carcinoma", "Cholangiocarcinoma", "Basal Cell Carcinoma", "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Thymoma", "Thymic Carcinoma", "Squamous Cell Carcinoma of the Penis", "Vulvar Carcinoma", "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy", "Malignant Adnexal Neoplasms", "Non-squamous Cell Salivary Gland Carcinoma" ], "interventions": [ { "name": "XmAb20717", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2018-07-10", "completion_date": "2022-09-06", "has_results": false, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 17, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517488" }, { "nct_id": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagogastric Tumors", "Gastric Cancer", "Gastric Tumor", "Esophageal Cancer", "Esophageal Neoplasms", "Esophageal Tumor", "GastroEsophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Gastroesophageal Junction Tumor", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-08-10", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510285" }, { "nct_id": "NCT06038578", "title": "A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2023-10-04", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Arlington", "state": "Texas" }, { "city": "Bedford", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06038578" }, { "nct_id": "NCT02082210", "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Hepatocellular Cancer", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Emibetuzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2014-03-07", "completion_date": "2018-01-24", "has_results": true, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082210" }, { "nct_id": "NCT01498289", "title": "S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 213, "start_date": "2012-02", "completion_date": "2019-09-19", "has_results": true, "last_update_posted_date": "2019-11-07", "last_synced_at": "2026-07-23T10:21:43.901Z", "location_count": 508, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498289" } ] }